Note: A story mentioned in this column, “Prime Signs Agreement With EMD Serono to Improve Mavenclad’s Cost-benefit Value,” was updated on June 15, 2020, to clarify that the agreement allows for possible reimbursement for Prime’s health plan clients, not patients directly. This column has been updated accordingly.
Is there hope for restoring myelin for people with MS? This company and several other corporate investors are betting several million that there is. The company is researching the use of a thyroid hormone to stimulate the production of mature oligodendrocytes, the cells that produce myelin.
Autobahn Therapeutics announced its launch with $76 million in financing to support work on therapies for central nervous system (CNS) disorders, including ABX-002, its lead candidate to treat diseases marked by the loss of myelin, such as multiple sclerosis (MS) and adrenomyeloneuropathy.
“We stand well-positioned to advance our pipeline with funding from the highest quality investors and pharmaceutical leaders who share our mission of improving life health for people affected by these conditions,” Kevin Finney, chairman and CEO of Autobahn, said in a press release.
Click here to read the full story.
If you buy a new bed, and within a reasonable time you find it doesn’t suit you, some stores will allow you to return it for a refund or exchange. A health insurance group has made a similar agreement with the company that markets Mavenclad (cladribine). Some of the medication will be compensated if it doesn’t help with MS symptoms. Is that type of program something that would affect your choice of disease-modifying therapies?
Prime Therapeutics has signed an agreement with EMD Serono providing financial compensation for Prime’s health plan clients in the case that their members stop taking Mavenclad (cladribine) over the typical treatment period.
The level of financial compensation will depend on the rate at which patients discontinue Mavenclad or switch to another MS therapy over the typical two-year treatment course.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?